FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

BROOKS Share Price Discussion

Brooks Laboratories Ltd.
Sector: Pharmaceuticals and health care
... Read more
BROOKS Long Term Analysts Rating
0/5 (0 Ratings)
BROOKS Share Price *
38 +0 (0%)
* (quote may be delayed)

Find answers to all your questions on live BROOKS message board: Is BROOKS buy or sell? Should I buy BROOKS shares? Why are BROOKS shares falling? Should I invest in BROOKS stock?


BROOKS Discussion Forum

@newsbot • Reputation: 1,933
Stocks in the news: Sun Pharma, Infosys, Pidilite, Kajaria Ceramics, Reliance Nippon Life
Kajaria Ceramics | Reliance Nippon Life AMC | Vadilal Industries | Satin Creditcare Network and Kingfa Science are stocks which are in the news today.
Moneycontrol
Like
reply
Reply

BUY BROOKS @55
SL 50 TGT OPEN #Positional
Like
reply
Reply
  • BROOKS - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization86.21
    Enterprise Value111.07
    Price to Earnings112
    Price to Book Value0.82
    Return on Capital Employed-0.11
    Return on Equity-0.12
    Face Value10
    Dividend YieldNA
  • BROOKS Share Price - Technicals

    keyboard_arrow_down
    BROOKS - 52 Week High₹63
    BROOKS - 52 Week Low₹22.3
  • BROOKS Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jan 2238.139.7537.638
    Jan 2138.538.737.838
    Jan 2039.939.937.938.7
    Jan 173740.353739.05
    Jan 1637.0537.7536.9537.4
  • BROOKS Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹33.83
    30 Day Moving Average₹31.71
    50 Day Moving Average₹30.92
    100 Day Moving Average₹32.6
    200 Day Moving Average₹39.41
  • BROOKS - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue55.7157.54-0.03
    Operating Profit-8.895.62-2.58
    Profit Before Tax-17.543.06-6.73
    Net Income-13.811.96-8.05
  • BROOKS - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds105.15114.48-0.08
    Total Liabilities62.868.25-0.08
    Total Assets167.95182.73-0.08
  • BROOKS - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity-6.189.6-1.64
    Cash from Investing Activity-5.14-16.31-0.68
    Cash from Financing Activity11.826.480.82
    Net Cash Flow0.51-0.23-3.22
  • BROOKS - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets-0.080.01
    Return on Equity-0.120.02
    Return on Capital Employed-0.110.03
  • BROOKS - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue-0.35
    3 Year CAGR Growth in Operating Profit-2.32
    3 Year CAGR Growth in EBIDTA-1.73
    3 Year CAGR Growth in Net Income-2.46
    3 Yr CAGR Growth - Diluted EPS-2.47
  • BROOKS - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue-0.3
    5 Year CAGR Growth in Operating Profit-1.85
    5 Year CAGR Growth in EBIDTA-1.82
    5 Year CAGR Growth in Net Income-2.93
    3 Yr CAGR Growth - Diluted EPS-2.93
  • BROOKS - Recent News

    keyboard_arrow_down
    NewsBot
    Aug 27 1:38 PM
    Stocks in the news: Sun Pharma, Infosys, Pidilite, Kajaria Ceramics, Reliance Nippon Life
    Moneycontrol
  • BROOKS - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. S...
    Aurobindo Pharma Ltd. Sector: Pharma...
    Biocon Ltd. Sector: Pharmaceuticals ...
    Cipla Ltd. Sector: Pharmaceuticals a...
    Lupin Ltd. Sector: Pharmaceuticals an...
    Dr. Reddy's Laboratories Ltd. Sector...
    Piramal Enterprises Ltd. Sector: Phar...
    Glenmark Pharmaceuticals Ltd. Sector...
    Divi's Laboratories Ltd. Sector: Pha...
    Strides Pharma Science Ltd. Sector: P...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.